Table 1 Patient and tumor characteristics according to the treatment group at the time of diagnosis.
Arm A | Arm B | p value | |
|---|---|---|---|
n (%) | n (%) | ||
Age (mean, SD) | 53 (± 11) | 48 (± 11) | 0.01b |
Comorbidity | 20 (40.0) | 32 (34.8) | 0.53 |
ECOG | 0.06 | ||
0 | 34 (68.0) | 48 (52.2) | |
1 | 16 (32.0) | 44 (47.8) | |
Clinical T stage | 0.58 | ||
T1–2 | 38 (76.0) | 66 (71.7) | |
T3–4 | 12 (24.0) | 26 (28.3) | |
Clinical N stage | 0.58 | ||
N0 | 5 (10.0) | 11 (12.0) | |
N1 | 15 (30.0) | 37 (40.2) | |
N2 | 23 (46.0) | 34 (37.0) | |
N3 | 7 (14.0) | 10 (10.8) | |
Clinical stage | 0.14 | ||
Operable | 20 (40.0) | 45 (48.9) | |
Locally advanced | 30 (60.0) | 43 (46.7) | |
Inflammatory | 0 (0.0) | 4 (4.3) | |
Hormone status | 0.99 | ||
ER and/or PR-positive | 31 (62.0) | 57 (62.0) | |
ER and PR-negative | 19 (38.0) | 35 (38.0) | |
Grade | 0.47 | ||
Gx/G1/G2 | 26 (52.0) | 42 (45.7) | |
G3 | 24 (48.0) | 50 (54.3) | |
Ki-67 levela (%) | 30 (7–90) | 40 (8–95) | 0.66 |
Lymphovascular invasion | 21 (42.0) | 41 (44.6) | 0.76 |
Perineural invasion | 15 (30.0) | 22 (23.9) | 0.43 |
Number of cyclesa | 4 (3–6) | 8 (6–8) | < 0.001b |
Neoadjuvant treatment completion | 46 (92.0) | 88 (95.7) | 0.45 |
